Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Biosenta Inc (ZRO) Stock Price & Analysis

3 Followers

ZRO Stock Chart & Stats

CA$0.05CA$0.00(0.00%)
At close: 4:00 PM EST
C$0.04C$0.06C$0.08Aug 31Sep 14Sep 30Oct 15Oct 28Nov 9
Day’s Range
CAD 0.05 - CAD 0.05
52-Week Range
CAD 0.01 - CAD 0.13
Previous Close
CAD 0.05
Volume
N/A
Average Volume (3M)
2,998
Market Cap
CAD 1.56M
Enterprise Value
CAD 1.95M
Total Cash (Recent Filing)
CAD 19.93K
Total Debt (Recent Filing)
CAD 7.52M
Price to Earnings (P/E)
―
Beta
1.07
Next Earnings
Feb 02, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Antimicrobial Technology Focus

A focused position in antimicrobial and odor-control applications gives Biosenta a defined product domain spanning commercial and consumer environments. This specialization can support continued development and commercialization efforts across multiple use cases as demand for microbial-control solutions persists.

Multiple Commercialization Routes

Biosenta’s stated commercialization model can use both product sales and partner-based licensing or distribution. Having several routes to market may allow the company to pursue customers without relying on one format, while licensing could provide access to external manufacturing and distribution capabilities.

Moderating Losses And Cash Burn

The moderation in cash burn and losses is a constructive direction, even though cash generation remains negative. If sustained, improving cash discipline could extend operating runway, reduce the pace of external funding needs, and provide a more stable base for commercializing the company’s technologies.

Bears Say

Unsustainable Profitability

Persistent losses, negative gross profit, and deeply negative operating margins show that Biosenta has not yet demonstrated a sustainable operating model. Continued weak profitability limits internally generated funding, increases dependence on financing, and makes execution of commercialization plans more difficult.

Stressed Balance Sheet

The combination of a substantial equity deficit and debt far exceeding the asset base indicates very limited financial flexibility. This structure raises solvency risk, restricts the company’s ability to absorb setbacks, and can constrain investment in product development or market expansion.

Ongoing Cash Consumption

Biosenta continues to consume cash rather than generate it from operations, despite some improvement from 2024. Ongoing negative operating cash flow can require repeated external funding, leaving the company vulnerable to financing constraints and limiting its ability to build durable commercial scale.

Biosenta Inc News

ZRO FAQ

What was Biosenta Inc’s price range in the past 12 months?
Biosenta Inc lowest stock price was C$0.01 and its highest was C$0.13 in the past 12 months.
What is Biosenta Inc’s market cap?
Biosenta Inc’s market cap is C$1.56M.
When is Biosenta Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Biosenta Inc’s earnings last quarter?
Biosenta Inc released its earnings results on Aug 28, 2026. The company reported -C$0.048 earnings per share for the quarter.
Is Biosenta Inc overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Biosenta Inc pay dividends?
Biosenta Inc does not currently pay dividends.
What is Biosenta Inc’s EPS estimate?
Biosenta Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosenta Inc have?
Biosenta Inc has 34,768,887 shares outstanding.
What happened to Biosenta Inc’s price movement after its last earnings report?
Biosenta Inc reported an EPS of -C$0.048 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biosenta Inc?
Currently, no hedge funds are holding shares in TSE:ZRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology